ChengDa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
ChengDa Pharmaceuticals's earnings have been declining at an average annual rate of -3.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.1% per year. ChengDa Pharmaceuticals's return on equity is 3.2%, and it has net margins of 17.6%.
Key information
-3.7%
Earnings growth rate
-12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 3.1% |
| Return on equity | 3.2% |
| Net Margin | 17.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ChengDa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 398 | 70 | 91 | 41 |
| 30 Jun 24 | 412 | 87 | 94 | 37 |
| 31 Mar 24 | 413 | 90 | 87 | 32 |
| 31 Dec 23 | 414 | 91 | 87 | 27 |
| 30 Sep 23 | 366 | 76 | 78 | 21 |
| 30 Jun 23 | 361 | 71 | 81 | 20 |
| 31 Mar 23 | 405 | 100 | 85 | 19 |
| 01 Jan 23 | 411 | 106 | 89 | 19 |
| 30 Sep 22 | 432 | 122 | 90 | 20 |
| 30 Jun 22 | 438 | 115 | 83 | 19 |
| 31 Mar 22 | 436 | 106 | 76 | 18 |
| 01 Jan 22 | 416 | 100 | 68 | 17 |
| 30 Sep 21 | 396 | 126 | 103 | 31 |
| 31 Dec 20 | 373 | 121 | 55 | 19 |
| 31 Dec 19 | 294 | 54 | 52 | 12 |
| 31 Dec 18 | 203 | 7 | 46 | 9 |
Quality Earnings: 301201 has a high level of non-cash earnings.
Growing Profit Margin: 301201's current net profit margins (17.6%) are lower than last year (20.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301201's earnings have declined by 3.7% per year over the past 5 years.
Accelerating Growth: 301201's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301201 had negative earnings growth (-7.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 301201's Return on Equity (3.2%) is considered low.